{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:07:19Z","timestamp":1765609639705,"version":"3.40.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T00:00:00Z","timestamp":1413158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/2046-4053-3-116","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T15:01:19Z","timestamp":1413212479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis"],"prefix":"10.1186","volume":"3","author":[{"given":"Eric","family":"Druyts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Thorlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,13]]},"reference":[{"key":"284_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","volume":"19","author":"B Vitiello","year":"2009","unstructured":"Vitiello B, Correll C, Van Zwieten-Boot B, Zuddas A, Parellada M, Arango C: Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009, 19: 629-635. 10.1016\/j.euroneuro.2009.04.008.","journal-title":"Eur Neuropsychopharmacol"},{"key":"284_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","volume":"47","author":"C Correll","year":"2008","unstructured":"Correll C: Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008, 47: 9-20. 10.1097\/chi.0b013e31815b5cb1.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"284_CR3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/070674371205700109","volume":"57","author":"S Alessi-Severini","year":"2012","unstructured":"Alessi-Severini S, Biscontri RG, Collins DM, Sareen J, Enns MW: Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry. 2012, 57 (1): 52-58.","journal-title":"Can J Psychiatry"},{"issue":"6","key":"284_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/cap.2010.0145","volume":"21","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Lam D, Patten SB: The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005\u20132009. J Child Adolescent Psychopharmacol. 2011, 21 (6): 537-543. 10.1089\/cap.2010.0145.","journal-title":"J Child Adolescent Psychopharmacol"},{"issue":"5","key":"284_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1517\/17425255.2011.562198","volume":"7","author":"S Caccia","year":"2011","unstructured":"Caccia S, Clavenna A, Bonati M: Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol. 2011, 7 (5): 591-608. 10.1517\/17425255.2011.562198.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"284_CR6","volume-title":"USA Today","author":"M Elias","year":"2006","unstructured":"Elias M: New antipsychotic drugs carry risks for children. USA Today. 2006, [ http:\/\/usatoday30.usatoday.com\/news\/health\/2006-05-01-atypical-drugs_x.htm ],"},{"key":"284_CR7","volume-title":"New York Times","author":"G Harris","year":"2008","unstructured":"Harris G: Use of antipsychotics in children is criticized. New York Times. 2008, [ http:\/\/www.nytimes.com\/2008\/11\/19\/health\/policy\/19fda.html?_r=0 ],"},{"key":"284_CR8","first-page":"385","volume":"17","author":"V Goffin","year":"1996","unstructured":"Goffin V, Shiverick K, Kelly P, Martial J: Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr Rev. 1996, 17: 385-410.","journal-title":"Endocr Rev"},{"key":"284_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1210\/edrv-7-2-169","volume":"7","author":"C Nicoll","year":"1986","unstructured":"Nicoll C, Mayer G, Russell S: Structural features of prolactins and growth hormones that can be related to their biological properties. Endocr Rev. 1986, 7: 169-203. 10.1210\/edrv-7-2-169.","journal-title":"Endocr Rev"},{"key":"284_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1023\/A:1022804817104","volume":"7","author":"I Forsyth","year":"2002","unstructured":"Forsyth I, Wallis M: Growth hormone and prolactin\u2014molecular and functional evolution. J Mammary Gland Biol Neoplasia. 2002, 7: 291-312. 10.1023\/A:1022804817104.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"284_CR11","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","volume":"65","author":"J Montgomery","year":"2004","unstructured":"Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, Josiassen R: Prevalence of hyperprolactinaemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004, 65: 1491-1498. 10.4088\/JCP.v65n1108.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"284_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","volume":"28","author":"U Halbreich","year":"2003","unstructured":"Halbreich U, Kinon BJ, Gilmore JA, Kahn LS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003, 28 (Suppl 1): 53-67.","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"284_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","volume":"61","author":"GM Anderson","year":"2007","unstructured":"Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B: Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007, 61 (4): 545-550. 10.1016\/j.biopsych.2006.02.032.","journal-title":"Biol Psychiatry"},{"issue":"11","key":"284_CR14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","volume":"64","author":"RL Findling","year":"2003","unstructured":"Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry. 2003, 64 (11): 1362-1369. 10.4088\/JCP.v64n1113.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 2","key":"284_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0306-4530(02)00130-0","volume":"28","author":"H Knegtering","year":"2003","unstructured":"Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ: What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuroendocrinology. 2003, 28 (Suppl 2): 109-123.","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"284_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","volume":"19","author":"DL Kleinberg","year":"1999","unstructured":"Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999, 19 (1): 57-61. 10.1097\/00004714-199902000-00011.","journal-title":"J Clin Psychopharmacol"},{"key":"284_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1192\/bjp.181.4.271","volume":"181","author":"HM Jones","year":"2002","unstructured":"Jones HM, Pilowsky LS: Dopamine and antipsychotic drug action revisited. Br J Psychiatry. 2002, 181: 271-275. 10.1192\/bjp.181.4.271.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"284_CR18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0031-6997(24)01483-2","volume":"53","author":"PG Strange","year":"2001","unstructured":"Strange PG: Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev. 2001, 53 (1): 119-133.","journal-title":"Pharmacol Rev"},{"key":"284_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","volume":"157","author":"S Kapur","year":"2000","unstructured":"Kapur S, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatr. 2000, 157: 514-520. 10.1176\/appi.ajp.157.4.514.","journal-title":"Am J Psychiatr"},{"issue":"8","key":"284_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2165\/11592020-000000000-00000","volume":"34","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Lam D, Ching H, Patten S: Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011, 34 (8): 651-668. 10.2165\/11592020-000000000-00000.","journal-title":"Drug Saf"},{"key":"284_CR21","first-page":"234","volume":"20","author":"J Ho","year":"2011","unstructured":"Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T, CAMESA guideline group: Recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry. 2011, 20: 234-241.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"issue":"1","key":"284_CR22","first-page":"1","volume":"22","author":"D Pfeiffer","year":"2012","unstructured":"Pfeiffer D, Br\u00fbl\u00e9-Brown D: Second-generation antipsychotics and cardiometabolic adverse reactions in children and adolescents. Canadian Adverse Reaction Newslett. 2012, 22 (1): 1-2.","journal-title":"Canadian Adverse Reaction Newslett"},{"issue":"2 Suppl","key":"284_CR23","first-page":"1","volume":"161","author":"A Lehman","year":"2004","unstructured":"Lehman A, Lieberman J, Dixon L, McGlashan T, Miller A, Perkinds D, Kreyenbuhl J, American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004, 161 (2 Suppl): 1-56.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"284_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","volume":"150","author":"R Tandon","year":"2013","unstructured":"Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S, Tsuang M, Van Os J, Carpenter W: Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013, 150 (1): 3-10. 10.1016\/j.schres.2013.05.028.","journal-title":"Schizophr Res"},{"key":"284_CR25","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J Higgins","year":"2009","unstructured":"Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions. 2009, London: The Cochrane Collaboration"},{"key":"284_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jclinepi.2011.04.015","volume":"65","author":"EA Akl","year":"2012","unstructured":"Akl EA, Sun X, Busse JW, Johnston BC, Briel M, Mulla S, You JJ, Bassler D, Lamontagne F, Vera C, Alshurafa M, Katsios CM, Heels-Ansdell D, Zhou Q, Mills E, Guyatt GH: The reliability and validity of estimating unclearly reported blinding status in randomized clinical trials. J Clin Epidemiol. 2012, 65: 262-267. 10.1016\/j.jclinepi.2011.04.015.","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"284_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, Group GW: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336 (7650): 924-926. 10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"7","key":"284_CR28","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chairmani A, Cadwell D, Higgins J: Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014, 9 (7): e99682-10.1371\/journal.pone.0099682.","journal-title":"PLoS One"},{"issue":"5","key":"284_CR29","doi-asserted-by":"publisher","first-page":"e2195","DOI":"10.1371\/journal.pntd.0002195","volume":"7","author":"GF Cota","year":"2013","unstructured":"Cota GF, de Sousa MR, Fereguetti TO, Rabello A: Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis. 2013, 7 (5): e2195-10.1371\/journal.pntd.0002195. doi: 10.1371\/journal.pntd.0002195","journal-title":"PLoS Negl Trop Dis"},{"issue":"20","key":"284_CR30","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004, 23 (20): 3105-3124. 10.1002\/sim.1875.","journal-title":"Stat Med"},{"key":"284_CR31","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1001\/2012.jama.11228","volume":"308","author":"E Mills","year":"2012","unstructured":"Mills E, Ioannidis J, Thorlund K, Schunemann H, Puhan M, Guyatt G: How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012, 308: 1246-1253. 10.1001\/2012.jama.11228.","journal-title":"JAMA"},{"key":"284_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-2288-12-111","volume":"12","author":"JJ Gagnier","year":"2012","unstructured":"Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C: Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature. BMC Med Res Methodol. 2012, 12: 111-10.1186\/1471-2288-12-111.","journal-title":"BMC Med Res Methodol"},{"key":"284_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","volume":"11","author":"JP Jansen","year":"2013","unstructured":"Jansen JP, Naci H: Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013, 11: 159-10.1186\/1741-7015-11-159. doi: 10.1186\/1741-7015-11-159","journal-title":"BMC Med"},{"issue":"2","key":"284_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011, 64 (2): 163-171. 10.1016\/j.jclinepi.2010.03.016.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"284_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/JCP.0b013e3182549259","volume":"32","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C: Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012, 32 (3): 309-316. 10.1097\/JCP.0b013e3182549259.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"284_CR36","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","volume":"21","author":"D Fraguas","year":"2011","unstructured":"Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C: Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011, 21 (8): 621-645. 10.1016\/j.euroneuro.2010.07.002.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"284_CR37","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1542\/peds.2011-2158","volume":"129","author":"JC Seida","year":"2012","unstructured":"Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, Vandermeer B, Dryden DM, Carrey N: Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics. 2012, 129 (3): e771-e784. 10.1542\/peds.2011-2158.","journal-title":"Pediatrics"},{"issue":"5","key":"284_CR38","first-page":"421","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M: The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014, 28 (5): 421-453.","journal-title":"CNS Drugs"},{"issue":"4","key":"284_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cap.2008.0120","volume":"19","author":"Y Roke","year":"2009","unstructured":"Roke Y, van Harten PN, Boot AM, Buitelaar JK: Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolescent Psychopharmacol. 2009, 19 (4): 403-414. 10.1089\/cap.2008.0120.","journal-title":"J Child Adolescent Psychopharmacol"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2046-4053-3-116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2046-4053-3-116\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2046-4053-3-116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2046-4053-3-116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:47:45Z","timestamp":1746416865000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/2046-4053-3-116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,13]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1186\/2046-4053-3-116","relation":{},"ISSN":["2046-4053"],"issn-type":[{"type":"electronic","value":"2046-4053"}],"subject":[],"published":{"date-parts":[[2014,10,13]]},"assertion":[{"value":"26 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"116"}}